• Welcome, Guest. Please login or register.
    May 30, 2020, 07:50:39 AM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:

thalpal.com

Click to visit us on Facebook


If you have any problems registering or signing in, please send an email to: andythalpal@yahoo.com
Please do not send questions about thalassemia to this address.


Administrators
Andy
Danielle

Thalassemia Patients and Friends and thalpal © A. Battaglia 2019





55292 Posts in 5909 Topics by 6204 Members
Latest Member: pareshdas1985

Forum Tip: 
You can now simply type thalpal.com into your browser and it will take you to this site. Tell your friends about this easy-to-remember name.
www.thalpal.com
« previous next »
Pages: 1 Go Down Print
Author Topic: bluebird bio Update from ASH 2016  (Read 2832 times)
Andy Battaglia
Administrator
Supreme Member
*****
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8656


Will thal rule you or will you rule thal?


« on: December 05, 2016, 10:04:45 PM »

bluebird bio presented at ASH this weekend.

Some highlights.

Quote
Updated interim clinical data from the Northstar (HGB-204) study of LentiGlobin drug product in transfusion-dependent β-thalassemia (TDT) confirm patients with non-β0/β0 genotypes and ≥12 months of follow-up have stopped regular transfusions; patients with β0/β0 genotypes and ≥12 months of follow-up had a median reduction in transfusion volume of 63%.

“In addition, we are pleased by the robust vector copy number and high proportion of LVV+ CD34+ stem cells in the drug product manufactured using transduction enhancers for the first patient to be treated in the Phase 3 Northstar-2 study. If the clinical correlation between drug product VCN and hemoglobin production observed in the Northstar study continues with drug product manufactured utilizing process 2, we are hopeful that LentiGlobin drug product with higher VCNs will consistently yield clinically meaningful outcomes for patients with TDT across all genotypes.”

The announcement from bluebird.
Quote
bluebird bio is honored to have presented new data from multi-center studies of LentiGlobinTM drug product in patients with transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) at the American Society of Hematology (ASH) Annual Meeting this week.
To summarize, bluebird bio provided updates including:
- Updated interim clinical data from the Northstar (HGB-204) study of LentiGlobin drug product in TDT confirm patients with non-β0/β0 genotypes and ≥12 months of follow-up have stopped regular transfusions; patients with β0/β0 genotypes and ≥12 months of follow-up had a median reduction in transfusion volume of 63%
- Drug product vector copy numbers (DP VCNs) for the first HGB-207 and HGB-206 patients who will be treated using LentiGlobin drug product made using our improved manufacturing process (process 2) are 2.9 and 3.3, respectively
- Updated interim clinical data from seven subjects in the HGB-206 study of LentiGlobin drug product in SCD underscore the need for recently implemented protocol amendments seeking to improve HbAT87Q production in this population
A full recap of what was presented at ASH can be found in the following two press releases:
http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=2227726
http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=2227319
Nick really said it best - “Our focus is learning, adjusting and implementing to innovate on behalf of the patients we aim to serve. This year we have made tremendous progress against this objective. In 2016, we focused on further enhancing our LentiGlobin programs in TDT and SCD by implementing high potential manufacturing and protocol amendments while advancing our lead bb2121 oncology program and commercialization capabilities. We are encouraged by the data presented at ASH and how that has informed our plans for 2017.”
Logged

Andy

All we are saying is give thals a chance.
Parin
Junior Member
***
Offline Offline

Location: USA

Gender: Male
Posts: 136


« Reply #1 on: December 06, 2016, 11:06:59 AM »

patients with β0/β0 genotypes and ≥12 months of follow-up had a median reduction in transfusion volume of 63%

This means frequency of transfusion decrease? is it going to complete stop?
Logged
Andy Battaglia
Administrator
Supreme Member
*****
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8656


Will thal rule you or will you rule thal?


« Reply #2 on: December 08, 2016, 10:40:15 AM »

I haven't seen the graph to see if there was any improvement in the  β0/β0 genotype patients, so I don't know if it has plateaued. It does mean transfusions are greatly reduced in these patients, but I don't know if they will ever be fully transfusion free from gene therapy, but with new drugs coming, they will probably become transfusion free once something like Luspatercept is available. bluebird does hope that once they begin trials on  β0/β0 patients with the new protocol that it will be enough to free them from transfusions.
Logged

Andy

All we are saying is give thals a chance.
CrazyPharm
Active Member
**
Offline Offline

Location: USA

Gender: Male
Posts: 43


« Reply #3 on: December 16, 2016, 04:58:56 AM »

Hi Andy,

Is bluebird planning a new protocol for b0/b0 patients? any idea when it will start? can you please point me to the reference I'd like to read more about it. thanks
Logged
Sharmin
Global Moderator
Supreme Member
*****
Offline Offline

Location: Canada

Gender: Female
Posts: 4155


Little A


« Reply #4 on: January 16, 2017, 06:11:47 PM »

CrazyPharm,

I don't know if bluebird has posted the information but both Andy and I have spoken with them and they are quite confident about their new protocol and its ability to free b0/b0 from transfusions.

I will post more once I get further information or once I have a link to this information.
Logged

Sharmin
Pages: 1 Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!